Koyo Kouoh, who will curate the 2026 Venice Biennale, has assembled a huge survey at the Bozar Centre for Fine Arts in ...
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
The order comes after Sony said it would take over distribution for the two syndicated game shows The post CBS Granted ...
2 Hilton Court: A 113,000-square foot office building last occupied by Daiichi Sankyo in 2016 was demolished last year to ...
Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback